SCHEMBL7798146

SCHEMBL7798146

CC(C)(C)OC(=O)C[C@@H]1C[C@@H](COc2ccc(-c3ccc(C(=N)N)c(F)c3)cc2)NC1=O

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.57
ITGA2B P08514 1/20 0.57
RARA P10276 1/20 0.36
RARB P10826 1/20 0.36
IRAK4 Q9NWZ3 13/20 0.36
MIF P14174 1/20 0.35
NAAA Q02083 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
PARP10 Q53GL7 2/20 0.34
PARP15 Q460N3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7284260 0.88 ITGB3 (0.74) ITGB3ITGA2BRARARARBIRAK4
SCHEMBL7323680 0.84 ITGB3 (0.47) ITGB3ITGA2BMIFGPR119
Hydrochloric Acid SCHEMBL7275246 0.83 ITGB3 (0.58) ITGB3ITGA2BIRAK4GPR119
Hydrochloric Acid SCHEMBL7275160 0.82 ITGB3 (0.58) ITGB3ITGA2BIRAK4NAAAGPR119
Hydrochloric Acid SCHEMBL7277371 0.81 ITGB3 (0.61) ITGB3ITGA2BIRAK4
SCHEMBL7273632 0.80 ITGB3 (0.51) ITGB3ITGA2BRARARARBIRAK4
SCHEMBL7285264 0.80 ITGB3 (0.53) ITGB3ITGA2BGPR119
SCHEMBL7276958 0.80 ITGB3 (0.61) ITGB3ITGA2BIRAK4GPR119
Hydrochloric Acid SCHEMBL7272653 0.79 ITGB3 (0.58) ITGB3ITGA2BIRAK4
SCHEMBL8884076 0.79 ITGB3 (0.52) ITGB3ITGA2BGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010034445-A1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION 2001-10-25 US disclosed
US-6159964-A Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2000-12-12 US disclosed
EP-0895475-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2000-08-23 EP disclosed
EP-0906103-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-04-07 EP disclosed
EP-0906103-A4 1999-04-07 EP disclosed
EP-0895475-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-10 EP disclosed
WO-1997024124-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-10 WO disclosed
WO-1997024122-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034445-A1 Vitronectin receptor antagonists ADGRF1, GPR174, CALCRL ITGB3 132/4885ITGA2B 106/4885RARA 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.